PRAX
Praxis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRAX
Praxis Precision Medicines, Inc.
A clinical-stage biopharmaceutical company that developing therapies for central nervous system disorders
Biological Technology
09/22/2015
10/16/2020
NASDAQ Stock Exchange
116
12-31
Common stock
99 High Street, 30th Floor, Boston, MA, 02110
--
Praxis Precision Medicines, Inc., was incorporated under the laws of the State of Delaware on September 22, 2015. The company is a clinical-stage biopharmaceutical company that translates genetic insights into the development of treatments for the central nervous system (CNS), a disease characterized by neuronal imbalance.
Earnings Call
Q2/2025
Estimate EPS-3.36
Actual EPS-3.31
Estimate Revenue157.13K
Actual Revenue0
Vormatrigine's Efficacy and Safety: Contradictions in Clinical Insights from Recent Earnings Calls
Aug 04,2025 01:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PRAX has released its 2025 Q3 earnings. EPS was reported at -3.36, versus the expected -3.49, beating expectations. The chart below visualizes how PRAX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
